Funds holding BridgeBio Oncology Therapeutics Inc
ISIN US1079241022 · United States
- Fund holders
- 40
- Of which ETFs
- 8 32 other funds
- Value held
- 45.5M $
- Share of capital
- 7.0 % of 80.2M shares on Aug 6, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1,422,900 | 10.8M $ | 0.00 % | 1.77 % | as of Jun 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 813,301 | 6.2M $ | 0.06 % | 1.01 % | as of Jun 30, 2026 ↗ |
| BlackRock Health Sciences Opportunities Portfolio BlackRock Funds | 673,766 | 6M $ | 0.10 % | 0.84 % | as of May 29, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 539,581 | 4.1M $ | 0.00 % | 0.67 % | as of Jun 30, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 306,024 | 2.3M $ | 0.03 % | 0.38 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 250,892 | 2.3M $ | 0.01 % | 0.31 % | as of May 31, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 240,300 | 2.2M $ | 0.04 % | 0.30 % | as of May 31, 2026 ↗ |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 227,258 | 2M $ | 0.01 % | 0.28 % | as of May 31, 2026 ↗ |
| T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC. | 222,512 | 1.7M $ | 0.01 % | 0.28 % | as of Jun 30, 2026 ↗ |
| Victory Small Cap Stock Fund Victory Portfolios III | 134,743 | 1.1M $ | 0.11 % | 0.17 % | as of Jul 31, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 93,339 | 837.3K $ | 0.48 % | 0.12 % | as of May 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 90,376 | 810.7K $ | 0.00 % | 0.11 % | as of May 31, 2026 ↗ |
| Royce Micro-Cap Fund ROYCE FUND | 87,617 | 667.6K $ | 0.16 % | 0.11 % | as of Jun 30, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 72,932 | 654.2K $ | 0.00 % | 0.09 % | as of May 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 49,459 | 443.6K $ | 0.00 % | 0.06 % | as of May 31, 2026 ↗ |
| Health Sciences Portfolio PACIFIC SELECT FUND | 40,663 | 309.9K $ | 0.08 % | 0.05 % | as of Jun 30, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 40,107 | 324.5K $ | 0.70 % | 0.05 % | as of Jul 31, 2026 ↗ |
| Royce Small-Cap Fund ROYCE FUND | 38,053 | 290K $ | 0.01 % | 0.05 % | as of Jun 30, 2026 ↗ |
| Schwab Total Stock Market Index Fund SCHWAB CAPITAL TRUST | 32,000 | 258.9K $ | 0.00 % | 0.04 % | as of Jul 31, 2026 ↗ |
| Royce Capital Fund - Micro-Cap Portfolio ROYCE CAPITAL FUND | 28,976 | 220.8K $ | 0.16 % | 0.04 % | as of Jun 30, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 28,792 | 219.4K $ | 0.00 % | 0.04 % | as of Jun 30, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 27,634 | 223.6K $ | 0.05 % | 0.03 % | as of Jul 31, 2026 ↗ |
| Schwab U.S. Broad Market ETF SCHWAB STRATEGIC TRUST | 27,500 | 246.7K $ | 0.00 % | 0.03 % | as of May 31, 2026 ↗ |
| Fidelity ZERO Total Market Index Fund Fidelity Concord Street Trust | 24,941 | 201.8K $ | 0.00 % | 0.03 % | as of Jul 31, 2026 ↗ |
| ACUITAS US MICROCAP FUND FORUM FUNDS II | 24,350 | 185.5K $ | 0.16 % | 0.03 % | as of Jun 30, 2026 ↗ |
| Fidelity ZERO Extended Market Index Fund Fidelity Concord Street Trust | 18,529 | 149.9K $ | 0.01 % | 0.02 % | as of Jul 31, 2026 ↗ |
| T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 15,774 | 120.2K $ | 0.02 % | 0.02 % | as of Jun 30, 2026 ↗ |
| Small Cap Core Fund Northern Funds | 15,579 | 118.7K $ | 0.03 % | 0.02 % | as of Jun 30, 2026 ↗ |
| Harbor Active Small Cap Growth ETF Harbor ETF Trust | 12,274 | 99.3K $ | 0.37 % | 0.02 % | as of Jul 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 7,754 | 62.7K $ | 0.05 % | 0.01 % | as of Jul 31, 2026 ↗ |
| Fidelity Flex Small Cap Index Fund Fidelity Salem Street Trust | 7,506 | 60.7K $ | 0.01 % | 0.01 % | as of Jul 31, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 7,262 | 55.3K $ | 0.02 % | 0.01 % | as of Jun 30, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 4,884 | 37.2K $ | 0.02 % | 0.01 % | as of Jun 30, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 4,825 | 36.8K $ | 0.00 % | 0.01 % | as of Jun 30, 2026 ↗ |
| VIP Extended Market Index Portfolio Variable Insurance Products Fund II | 4,161 | 31.7K $ | 0.01 % | 0.01 % | as of Jun 30, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 3,606 | 27.5K $ | 0.06 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST | 3,155 | 24K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 1,414 | 10.8K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| VIP Total Market Index Portfolio Variable Insurance Products Fund II | 1,180 | 9K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Pacer WealthShield ETF Pacer Funds Trust | 378 | 3.1K $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.70 % | as of Jul 31, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 0.48 % | as of May 31, 2026 ↗ |
| Harbor Active Small Cap Growth ETF Harbor ETF Trust | 0.37 % | as of Jul 31, 2026 ↗ |
| ACUITAS US MICROCAP FUND FORUM FUNDS II | 0.16 % | as of Jun 30, 2026 ↗ |
| Royce Capital Fund - Micro-Cap Portfolio ROYCE CAPITAL FUND | 0.16 % | as of Jun 30, 2026 ↗ |
| Royce Micro-Cap Fund ROYCE FUND | 0.16 % | as of Jun 30, 2026 ↗ |
| Victory Small Cap Stock Fund Victory Portfolios III | 0.11 % | as of Jul 31, 2026 ↗ |
| BlackRock Health Sciences Opportunities Portfolio BlackRock Funds | 0.10 % | as of May 29, 2026 ↗ |
| Health Sciences Portfolio PACIFIC SELECT FUND | 0.08 % | as of Jun 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.06 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 40 | +15 | 5,646,297 | +68.7 % |
| 2026Q2 | 25 | +7 | 3,346,914 | +3.2 % |
| 2026Q1 | 18 | +9 | 3,244,689 | +49.8 % |
| 2025Q4 | 9 | 2,166,554 |
Institutional managers
63 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Cormorant Asset Management, LP | 17,878,594 | 160M $ | as of Mar 31, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4,885,446 | 43.7M $ | as of Mar 31, 2026 |
| Omega Fund Management, LLC | 3,289,661 | 29.4M $ | as of Mar 31, 2026 |
| EcoR1 Capital, LLC | 2,823,126 | 25.3M $ | as of Mar 31, 2026 |
| Alphabet Inc. | 2,823,126 | 25.3M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 2,818,348 | 25.2M $ | as of Mar 31, 2026 |
| ENAVATE SCIENCES GP, LLC | 2,626,946 | 23.5M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 2,528,762 | 22.6M $ | as of Mar 31, 2026 |
| NOVO HOLDINGS A/S | 2,185,923 | 19.6M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 2,088,297 | 18.7M $ | as of Mar 31, 2026 |
| Laurion Capital Management LP | 1,922,656 | 17.2M $ | as of Mar 31, 2026 |
| ARMISTICE CAPITAL, LLC | 1,328,000 | 11.9M $ | as of Mar 31, 2026 |
| Aisling Capital Management LP | 1,018,018 | 9.1M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 868,213 | 7.8M $ | as of Mar 31, 2026 |
| Octagon Capital Advisors LP | 719,000 | 6.4M $ | as of Mar 31, 2026 |
| ROYCE & ASSOCIATES LP | 636,522 | 5.7M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 579,234 | 5.2M $ | as of Mar 31, 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | 541,181 | 4.7M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 437,889 | 3.9K $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 400,000 | 3.6M $ | as of Mar 31, 2026 |
| Ensign Peak Advisors, Inc | 320,874 | 2.9M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 290,806 | 2.6M $ | as of Mar 31, 2026 |
| Casdin Capital, LLC | 282,312 | 2.5M $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 270,231 | 2.4M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 265,954 | 2.4M $ | as of Mar 31, 2026 |
Declared shareholders of BridgeBio Oncology Therapeutics Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Bihua Chen and 7 others | 22.32 % | 17,878,594 | as of Jul 1, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Funds holding BridgeBio Oncology Therapeutics Inc". https://titelia.com/en/stocks/bridgebio-oncology-therapeutics-inc-US1079241022